Target intelligence / Profile preview

Opportunistic gut pathogens

Molecular classification
Other, Microorganisms
01

Overview

Opportunistic gut pathogens are a diverse group of microorganisms, including bacteria like Clostridioides difficile and fungi like Candida albicans, that typically reside harmlessly in the gut but cause disease when the host's internal environment is altered (Nature Reviews Microbiology, 2013). These alterations often stem from antibiotic use, which depletes the protective commensal microbiota, or from host immunosuppression (Cell Host & Microbe, 2016). Once the ecological balance is shifted, these pathogens can rapidly proliferate and deploy virulence factors such as toxins that damage the intestinal epithelium (CDC, 2019). Clinically, they are responsible for a wide range of conditions, from antibiotic-associated diarrhea to life-threatening systemic sepsis (The Lancet Infectious Diseases, 2014). Pharmacological intervention primarily involves targeted or broad-spectrum antimicrobials, though these carry the risk of promoting drug resistance and further dysbiosis (Journal of Clinical Investigation, 2011). Modern therapeutic approaches are increasingly exploring the use of fecal microbiota transplantation (FMT) and defined microbial consortia to restore colonization resistance and suppress these opportunistic populations (New England Journal of Medicine, 2013).

Other names
PathobiontsOpportunistic enteric pathogensGut-derived pathogensAccidental pathogens
02

Mechanism of action

Inhibition of bacterial cell wall synthesis, inhibition of protein synthesis, disruption of DNA replication, and restoration of microbial ecology through competitive exclusion.

03

Biological functions

ColonizationVirulence factor productionMetabolismBiofilm formationToxin secretion
04

Disease associations

InfectionGastrointestinal diseaseSepsisInflammationAntibiotic-associated diarrhea
05

Safety considerations

Antimicrobial resistanceMicrobiome dysbiosisOvergrowth of secondary pathogensSystemic toxicity of broad-spectrum agentsRisk of recurrent infection
06

Interacting drugs

Vancomycin

5 more in the full profile.

07

Biomarkers

Fecal toxin assays16S rRNA sequencingMetagenomic profilingFecal calprotectinCulture-based identification

Beyond the preview

Go deeper on Opportunistic gut pathogens.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Opportunistic gut pathogens.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call